






Latvia

	Target achieved	Progress	Regress
 <p>Reduce by 9% the total consumption of antibiotics in humans</p> <p>Defined daily doses (DDDs) per 1 000 inhabitants per day</p>	2019 baseline	13.9	-
	2023	14.9	+7.0%
	2030 TARGET	12.6	-9%
 <p>At least 65% of the total consumption of antibiotics in humans belongs to the 'Access' group of antibiotics</p> <p>As defined in the AWARe classification of the WHO</p> <p><small>*Percentage point difference from 2019.</small></p>	2019 baseline	68.6%	-
	2023	71.6%	+3%*
	2030 TARGET	65%	-
 <p>Reduce by 6% the total incidence of bloodstream infections with meticillin-resistant <i>Staphylococcus aureus</i> (MRSA)</p> <p>Number per 100 000 population</p>	2019 baseline	1.9	-
	2023	1.5	-22.5%
	2030 TARGET	1.8	-6%
 <p>Maintain at baseline level the total incidence of bloodstream infections with third-generation cephalosporin-resistant <i>Escherichia coli</i></p> <p>Number per 100 000 population</p>	2019 baseline	5.0	-
	2023	6.9	+37.2%
	2030 TARGET	5.0	-
 <p>Maintain at baseline level the total incidence of bloodstream infections with carbapenem-resistant <i>Klebsiella pneumoniae</i></p> <p>Number per 100 000 population</p>	2019 baseline	0	-
	2023	0.9	Not applicable*
	2030 TARGET	0	-

* For a baseline of 0, it was not possible to calculate the percentage of increase